FSE

Awakn Life Sciences Signs MOU with Maps

Retrieved on: 
Wednesday, January 19, 2022 - 12:30pm
Disability, KARE, Forward-looking statement, PTSD, Research, FSE, News, Alcoholism, Clinical trial, Multidisciplinary Association for Psychedelic Studies, Ketamine, Addiction, MDMA, Safety, University, CEO, MAPS, Disease, UoE, American Journal, Psychiatry, Reduction, The American Journal of Psychiatry, Phrase, AUD, Company, Diagnosis, Education, Conditional sentence, Therapy, Family, Charity Navigator, NEO, Partnership, Pharmaceutical industry, Psychopharmacology

Agreement to Explore a Partnership for MDMA-Assisted Therapy for Treatment of Alcohol Use Disorder in Europe

Key Points: 
  • Under the terms of this MOU, Awakn will explore a data licensing agreement with MAPS to support Awakn's Phase IIb and planned Phase III studies for MDMA-assisted therapy for AUD in Europe.
  • Awakn and MAPS will also assess a partnership to secure marketing authorisation/regulatory approval for the ethical commercialization of MDMA-assisted therapy for the treatment of AUD in Europe.
  • "We're delighted to be entering into this MoU with AWAKN which holds great promise for people suffering from AUD."
  • About Awakn Life Sciences Corp.
    Awakn Life Sciences is a biotechnology company, researching, developing, and delivering psychedelic therapeutics to better treat addiction.

EnerSpar and Israeli-Based Nurexone Announce Definitive Agreement

Retrieved on: 
Tuesday, January 18, 2022 - 10:13pm
Canada Business Corporations Act, FSE, Treasury, Consolidation, Policy, Tel Aviv University, CAD, Exosome, Ramot at Tel Aviv University, Institute of technology, RATS, Issuer, Good, Related party transaction, University, Agreement, Company, Spinal cord, NEX, Technology, TSX Venture Exchange, TSX, Transaction, Warrant, Institute, Cryptocurrency, Security (finance), Technion – Israel Institute of Technology

Calgary, Alberta--(Newsfile Corp. - January 18, 2022) - EnerSpar Corp. (TSXV: ENER) (FSE: 5E0) ("EnerSpar" or the "Company") is pleased to announce that they have entered into an arm's length securities exchange agreement dated January 3, 2022 (the "Agreement"), with Nurexone Biologic Ltd. ("Nurexone") and the shareholders of Nurexone (collectively, the "Vendors"), pursuant to which EnerSpar and Nurexone propose to complete a business combination (the "Proposed Transaction").

Key Points: 
  • Calgary, Alberta--(Newsfile Corp. - January 18, 2022) - EnerSpar Corp. (TSXV: ENER) (FSE: 5E0) ("EnerSpar" or the "Company") is pleased to announce that they have entered into an arm's length securities exchange agreement dated January 3, 2022 (the "Agreement"), with Nurexone Biologic Ltd. ("Nurexone") and the shareholders of Nurexone (collectively, the "Vendors"), pursuant to which EnerSpar and Nurexone propose to complete a business combination (the "Proposed Transaction").
  • Pursuant to the Agreement, EnerSpar will acquire each ordinary share of Nurexone in exchange for 17 post-Consolidation (as herein defined) EnerSpar shares from treasury (the "Consideration Shares").
  • Prior to the consummation of the Proposed Transaction, EnerSpar will, subject to the approval of EnerSpar Shareholders, consolidate all the issued and outstanding common shares of EnerSpar ("EnerSpar Shares") on the basis of 10 pre-consolidation EnerSpar Shares for each one post-consolidation EnerSpar Share (the "Consolidation").
  • Each Nurexone Private Placement Unit will consist of one Nurexone Share and one ordinary purchase warrant of Nurexone (each a "Nurexone Offering Warrant").

ALX Resources Corp. Begins Drilling Program at the Alligator Lake Gold Project, SK

Retrieved on: 
Wednesday, January 19, 2022 - 12:30pm
Quartz, SMDC, Palladium, Corporate communication, First Nations, Public health, Javelin, EM, TSX Venture Exchange, Risk, Nature, Government, Project, Draco, Mining, Denison Mines, Gold, Company, Financial statement, Max-min fairness, ALX, Platinum, Frankfurt Stock Exchange, Forward-looking statement, SEDAR, FSE, News, Copper, Provincial, Development corporation, Metal, Government House (Saskatchewan), Nine Months, Program, Mineral, National instrument, OTC, Uranium, Analysis, Board, Road, Amusement arcade, BC, Alligator

Vancouver, British Columbia--(Newsfile Corp. - January 19, 2022) - ALX Resources Corp. (TSXV: AL) (FSE: 6LLN) (OTC: ALXEF) ("ALX" or the "Company") is pleased to announce that a diamond drilling program is underway at the Alligator Lake Gold Project ("Alligator", or the "Project") located approximately 165 kilometres (103 miles) northeast of La Ronge, SK, Canada.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - January 19, 2022) - ALX Resources Corp. (TSXV: AL) (FSE: 6LLN) (OTC: ALXEF) ("ALX" or the "Company") is pleased to announce that a diamond drilling program is underway at the Alligator Lake Gold Project ("Alligator", or the "Project") located approximately 165 kilometres (103 miles) northeast of La Ronge, SK, Canada.
  • Alligator is the subject of an option agreement where ALX can earn up to an 80% interest in the Project (see ALX news release dated March 15, 2021 ).
  • The 2022 drilling program consists of up to eight (8) NQ-size diamond drill holes totaling approximately 1,000 metres.
  • Forward-looking statements in this news release include: the Alligator Lake Gold Project ("Alligator") is prospective for gold and base metals mineralization, the Company's plans to undertake exploration activities at Alligator, and expend funds on Alligator.

Gravity Pilot Plant Installed at Canada Silver Cobalt's Temiskaming Testing Labs for High-Grade Silver Tailings Testing

Retrieved on: 
Tuesday, January 18, 2022 - 12:45pm
Technical, FSE, News, Copper, Water, Technical report, Metal, Silver, National instrument, Mining, XRF, Gold, Nickel, EV, Company, NRC, CCW, Laboratory, NI, NMC, Graal, Sulfide, Cobalt, Gowganda

The installation of the gravity pilot plant at Temiskaming Testing Labs will be commissioned to optimize plant performance. It is designed to process high-grade stamp mill tailings and waste rock into concentrate feed for the Re-2Ox process.

Key Points: 
  • Company owns two of the three known high-grade silver stamp mill tailings in the Cobalt camp.
  • Beaver tailings were sonic drilled by the company last year with silver grades from 314 to 14 grams per tonne.
  • The reintegrated Re-2Ox process will be tested for the recovery of silver from the gravity concentrate.
  • The gravity pilot plant is designed to operate at one tonne per hour of high-grade silver tailings.

Roscan Gold Corp. Announces Drilling Results Confirm the High Grade and Mineralization Continuity at Mankouke South

Retrieved on: 
Tuesday, January 18, 2022 - 11:00am
Diamond, ID, MS3, RC, FSE, News, Kofi, Oklo, Iamgold, MS2, B2Gold, Gold, National instrument, MS1, CEO, ROS, DDH, Economics, OTC Markets Group, NI 43-101, National Instrument 43-101, Company, ALS, Gold Corporation, Laboratory, Acquisition, Rare-earth element, Uranium, Risk management, Amusement arcade, Potash

Intersects 4.66 gpt gold over 41 meters and 3.18 gpt gold over 26 meters at MS1

Key Points: 
  • MS1 drilling has confirmed additional mineralization outside currently defined areas and has confirmed MS1's excellent continuity that will be included in the upcoming resource estimate.
  • The drilling at the MS1 Target in Mankouke South (the main resources target), demonstrates the mineralization continuity at depth and dipping west, which remains open.
  • Main Mankouke South Zone (MS1) - Recent Drilling Confirms Mineralization occurs in the zones which received less density of drilling in the 2020 and 2021 previous drilling campaigns.
  • Roscan Gold Corporation is a Canadian gold exploration company focused on the exploration and acquisition of gold properties in West Africa.

DGAP-News: wallstreet:online doubles securities accounts and assets under custody in 2021 - Smartbroker grows by 140% to 200,000 accounts

Retrieved on: 
Wednesday, January 19, 2022 - 8:26pm
FSE, Federal, Wall, Group, AUC Libraries and Learning Technologies, Federal Financial Supervisory Authority, ISIN, Growth, CEO, AG, Review, Time, Neo, Company, Mission statement, Financial adviser, Financial services, Bank

The Group was able to more than double the number of securities accounts as well as assets under custody during the past year.

Key Points: 
  • The Group was able to more than double the number of securities accounts as well as assets under custody during the past year.
  • As of 31 December 2021, the subsidiary wallstreet:online capital AG managed around 240,000 securities accounts, of which 200,000 through Smartbroker, the Group's multiple full-service neo broker.
  • wallstreet:online capital AG is by now the largest neo broker operator in Germany measured by assets under custody.
  • Savings plans are likewise very popular: the number of active savings plans increased by 170% to 105,000 at the end of 2021.

DGAP-News: DATAMETREX REPORTS $20M IN CASH ON THE BALANCE SHEET FROM OPERATION

Retrieved on: 
Wednesday, January 19, 2022 - 8:24pm
FSE, Health and Safety Executive, Perception, CEO, Machine learning, Solution, DGAP, News, Artificial intelligence, Company, TSX Venture Exchange, DM, Security (finance), Bank, Online shopping, Cryptocurrency

Toronto, Canada, January 18, 2022 - Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTCQB: DTMXF) (the "Company" or "Datametrex") is pleased to announce that the Company currently has approximately $20M in cash and cash equivalent (marketable securities) on the balance sheet.

Key Points: 
  • Toronto, Canada, January 18, 2022 - Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTCQB: DTMXF) (the "Company" or "Datametrex") is pleased to announce that the Company currently has approximately $20M in cash and cash equivalent (marketable securities) on the balance sheet.
  • Over the last few quarters, the Company has had strong positive cash flow from its operations, which is attributed to the current strong balance sheet.
  • The cash balance is twenty times what it was valued in the same period of 2019.
  • Datametrex believes there will be continuous growth in revenue and profitability from its operations, which will generate stronger positive cash flow for the Company in 2022, resulting in a stronger balance sheet and cash position.

DGAP-News: EcoGraf Limited: Australian Lithium-ion BAM Facility Update

Retrieved on: 
Wednesday, January 19, 2022 - 8:23pm
BAM, Mineral, FSE, EGR, FMK, Samsung, US, Atmosphere, OTCQX, ASX, SK Group, EV, Company, Noise, Patent, LG Chem, Rare-earth element

EcoGraf Limited (EcoGraf or the Company) (ASX: EGR; FSE: FMK; OTCQX: ECGFF) is pleased to announce the following activities at its new EcoGraf(TM) Battery Anode Material (BAM) Facility in Western Australia.

Key Points: 
  • EcoGraf Limited (EcoGraf or the Company) (ASX: EGR; FSE: FMK; OTCQX: ECGFF) is pleased to announce the following activities at its new EcoGraf(TM) Battery Anode Material (BAM) Facility in Western Australia.
  • Completed process vendor equipment test work that confirmed suitability, resulting in final equipment selection and equipment guarantees.
  • Finalised regulatory permitting and approvals studies covering noise, air and bushfire management that support regulatory submissions (refer announcement Battery Anode Material Facility Development Approvals dated 25 October 2021).
  • The Company's state-of-the-art Battery Anode Material Facility in Western Australia will use its unique, patent pending EcoGraf(TM) HFfree processing technology.

Clearmind Medicine to Host “Psychedelic for Alcoholism: From Molecule to Medicine” Virtual Event on January 26

Retrieved on: 
Wednesday, January 19, 2022 - 2:00pm
Molecule, Medicine, Business development, Research, FSE, Alcoholism, GLOBE, Binge drinking, EST, OTC Markets Group, SMART Business Advisory and Consulting, Company, Doctor of Philosophy, Therapy, CSE, FDA, MEAI, Acquisition, Pharmaceutical industry

TORONTO, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTC Pink: CMNDF) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, is pleased to announce it will be hosting Psychedelics For Alcoholism, a free, live virtual event highlighting Clearmind’s patented MEAI molecule "From Molecule to Medicine: The Clinical Trial Pathway".

Key Points: 
  • The online event will be held on January 26, 2022, commencing at 12 p.m. EST, registration is open and free to all.
  • The event will be hosted by Shannon Smadella, Spokesperson & Business Advisory of World Psychedelic Day, and will feature Adi Zuloff-Shani, PhD, Chief Executive Officer of Clearmind and Adjunct Prof. Mark Haden, Clearmind's VP of Business Development.
  • Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder.
  • Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.

Recce Pharmaceuticals Announces Positive Safety Data from Second Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327

Retrieved on: 
Wednesday, January 19, 2022 - 1:00pm
Sepsis, FSE, Human, Degenerative disease, Clinical trial, PEW, Gram-negative bacteria, Virus, Safety, Vital signs, Infection, GLOBE, ASX, RCE, Bacteria, Pharmacokinetics, Synthetic, Pew, Company, Recce, CMAX, GAIN, Male, FDA, Trial, Pharmaceutical industry, Dietary supplement, Vaccine

SYDNEY, Australia, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (the Company), the company developing new classes of synthetic anti-infectives, is pleased to report further positive data from its Phase I intravenous (IV) clinical trial of RECCE® 327 (R327), demonstrating safety and tolerability among seven healthy male subjects in cohort two. Based upon these clinical data readouts, an Independent Safety Committee has approved a tenfold increase from the initial dosing of cohort one (50mg) and a threefold increase from cohort two (from 150mg to 500mg) among 7-10 healthy subjects (cohort three). Subjects are expected to be recruited this week and dosed immediately thereafter at Adelaide’s CMAX clinical trial facility.

Key Points: 
  • Subjects are expected to be recruited this week and dosed immediately thereafter at Adelaides CMAX clinical trial facility.
  • We are pleased to see R327 (150mg) was successfully tolerated as an intravenous infusion in cohort two subjects, said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • The Phase I trial is an ascending dose, randomized, placebo-controlled, parallel, double-blind, single-dose study being conducted at Adelaide's CMAX clinical trial facility.
  • RECCE 327 is not yet market approved for use in humans with further clinical testing required to fully evaluate safety and efficacy.